timolol maleate ophthalmic solution / Generic mfg. - LARVOL DELTA

Comparative efficacy and safety of pharmacologic, laser, and combination therapies for infantile hemangioma: a systematic review and network meta-analysis with evidence certainty assessment. (PubMed, Front Pharmacol) - "Regarding the primary endpoint, intralesional bleomycin combined with oral propranolol yielded significantly higher excellent response rates than oral propranolol alone (RR = 1.55, 95% CI 1.28-1.89; high certainty). Topical timolol with intralesional lauromacrogol (RR = 7.98, 95% CI 1.52-41.79) and oral propranolol with corticosteroids (RR = 2.00, 95% CI 1.03-3.88) showed higher excellent response rates, supported by moderate-certainty evidence...Oral atenolol was associated with numerically lower recurrence rates compared to oral propranolol, but the difference did not reach statistical significance (RR = 0.64, 95% CI 0.32-1.28; moderate certainty)...Defining precise risk-benefit profiles requires rigorous head-to-head trials utilizing uniform outcome measures. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261388356; Identifier: CRD420261388356."

Journal • Retrospective data • Review • Oncology

Adrenergic Pathways Mediate Circadian IOP Rhythm in Rats. (PubMed, Invest Ophthalmol Vis Sci) - "Agonists and antagonists of β- (isoproterenol and timolol), α1- (phenylephrine and bunazosin), and α2- (brimonidine and yohimbine) receptors were applied topically to the cornea during subjective day (SD) and subjective night (SN) in DD. All are necessary to raise IOP during SN since inactivation of any individual pathway drops IOP fully back to daytime levels. β- and α1-receptor activation is also singularly sufficient to raise IOP during SD to nighttime levels, whereas α2-receptors play a more complex role in IOP regulation."

Journal • Preclinical

Population Pharmacokinetics of Topical Timolol Maleate Gel in Healthy Volunteers and Infants With Superficial Infantile Hemangioma. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "Overall, systemic exposure following administration of this topical timolol maleate gel formulation was limited, supporting its favorable safety profile in infants with superficial IH. These quantitative findings may help guide its rational clinical use."

Journal • PK/PD data • Ophthalmology

Topical Timolol and Hyaluronic Acid: A Novel Approach to a Recalcitrant Post-Saphenectomy Kite-Shaped Ulcer (EADV 2026) - No abstract available

Efficacy and safety of topical timolol in chronic venous ulcers: A randomized controlled trial. (EADV 2026) - No abstract available

Clinical • Venous Ulcer

Clinical Characteristics, Management, and Complications of Infantile Hemangiomas Involving the Ear and Periauricular Region. (PubMed, Pediatr Dermatol) - "Given their location and potential for anatomic deformity and functional impairment, ear and periauricular IH may require intervention. A majority of patients in this cohort required treatment, most commonly for risk of anatomic deformity. The study is limited by the retrospective design and inclusion of patients seen before beta-blockers were available for IH management."

Journal • Otorhinolaryngology • Pediatrics

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: Glaukos Corporation | Phase classification: P2/3 ➔ P2 | N=610 ➔ 110

Enrollment change • Phase classification • Glaucoma • Ophthalmology

Engineering and Characterisation of 3D-Printed Timolol Maleate Implants for Long-Acting Glaucoma Treatment. (PubMed, AAPS J) - "The biocompatibility study showed no significant cytotoxicity, with fibroblast viability exceeding 80%. These findings suggest that TM-loaded implants could provide a more effective, sustained-release alternative for glaucoma treatment."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Soluble ocular insert of brinzolamide and timolol maleate: in-vitro, ex-vivo and in-vivo characterization. (PubMed, Ther Deliv) - "The short-term stability testing indicated that the ocular insert retained the characteristics of %Transmittance, pH, Assay and % drug release. Overall, the results suggest that for better therapeutic efficacy and adherence in glaucoma treatment, the dual-drug loaded ocular insert provides a new, patient-friendly substitute for traditional ophthalmic dosage forms."

Journal • Preclinical • Glaucoma • Ophthalmology

A Phase 2a study comparing the efficacy, safety and tolerability of pregabalin eye drops compared with timolol eye drops in adults with glaucoma or high eye pressure. (ANZCTR) - P2 | N=96 | Not yet recruiting | Sponsor: Tavo Biotherapeutics Australia Pty Ltd

New P2 trial • Cardiovascular • Glaucoma • Ophthalmology

Recognition and Management of Ulcerative Infantile Hemangioma: Risk Factors, Diagnosis, and Prognosis. (PubMed, Pediatr Ann) - "Condition-dependent treatments, including oral propranolol (starting at 1 mg/kg or less daily, maintenance at 2 to 3 mg/kg daily), timolol prophylaxis, and wound management care combined with laser therapy, shorten therapy duration and minimize recurrence. Surgery is indicated for life-threatening cases (eg, chest wall hemangiomas requiring transfusion or airway obstruction) and high-morbidity cases (eg, lip lesions affecting speech or periorbital lesions impairing vision). The Infantile Hemangioma Referral Score helps clinicians identify high-risk patients who require prompt referral, thereby preventing delayed treatment."

Journal • Review • Infectious Disease • Oncology

Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing (clinicaltrials.gov) - P2 | N=220 | Not yet recruiting | Sponsor: University of California, Davis | Initiation date: Jun 2026 ➔ Oct 2026

Trial initiation date

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Biomarker • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Liposomal Gel for enhancing topical efficacy of timolol maleate against proliferating superficial infantile hemangiomas. (PubMed, Int J Pharm ) - "Critically, the optimized formulation exhibited no skin irritation and no systemic toxicity. These findings highlight that the TM-lipogel provides enhanced transdermal delivery with deeper tissue penetration, representing a highly effective and safe transdermal strategy for IH therapy."

Journal • Oncology • HIF1A • MMP9 • NOS3

Medicine shortages and glaucoma care: a time-series analysis indicating population-level consequences of a national timolol eye drop shortage. (PubMed, Int J Clin Pharm) - "The timolol shortage disrupted access to a cornerstone first-line treatment for glaucoma. Regulatory intervention through the approval of imported products partially mitigated the shortage but did not restore utilisation to pre-shortage levels in Australia. Future shortage management strategies should prioritise rapid policy activation and closer alignment of imported products with formulations routinely available in Australia."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: EyeD Pharma | Phase classification: P1 ➔ P1/2 | N=18 ➔ 42

Enrollment change • Phase classification • Cardiovascular • Cataract • Glaucoma • Ophthalmology

Prophylactic Use of Timolol Maleate to Prevent Intraocular Pressure Elevation After Nd:YAG Laser Posterior Capsulotomy (clinicaltrials.gov) - P=N/A | N=210 | Completed | Sponsor: CMH Multan Institute of Medical Sciences

New trial • Cardiovascular • Cataract • Glaucoma

A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations. (PubMed, Pediatr Dermatol) - "Options for hemangioma treatment include systemic beta-blockers such as propranolol, atenolol, and nadolol, and the topical beta-blocker timolol...Recent pharmacological and technological advances in the medical management of vascular anomalies have decreased the need for surgery in many patients while also leading to improved outcomes and quality of life. This review will guide the dermatologist through the current medical treatment landscape for vascular malformations."

Journal • Review • Dermatology • Oncology • Pediatrics

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2 | N=252 | Completed | Sponsor: Bausch & Lomb Incorporated | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

From Chemistry to Clinic: A Review of Latanoprostene Bunod and Its Therapeutic Potential. (PubMed, Mini Rev Med Chem) - "In the phase III APOLLO and LUNAR trials, LBN demonstrated efficacy comparable to, and in some analyses greater than, timolol 0.5%. Overall, current evidence supports LBN as an effective and well-tolerated therapeutic option for patients with OAG or ocular hypertension. Continued improvements in synthetic methodologies may facilitate cost-effective production and broader clinical accessibility."

Journal • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Preparation and Characterization of a Low-Molecular-Weight Chitosan Nanoparticle-Based Ocular Formulation for Enhanced Permeation of Timolol Maleate. (PubMed, Curr Drug Deliv) - "The TM-based nanoparticle formulation enhanced corneal permeation and sustained TM release, offering a promising approach to improve ocular bioavailability and therapeutic efficacy."

Journal • Glaucoma • Ophthalmology

Topical Timolol for Peritoneal Dialysis Catheter Exit-Site Granulomas: First Report of Successful Use in CAPD Patients. (PubMed, Semin Dial) - "Topical 0.5% timolol maleate may represent a safe, non-invasive, and effective treatment option for peritoneal dialysis exit-site granulomas. Larger studies are warranted to establish its efficacy in larger cohorts."

Journal • Infectious Disease • Ophthalmology

Topical Sirolimus Therapy for Agminated Pyogenic Granulomas: A Two-Case Report. (PubMed, Pediatr Dermatol) - "PGs generally respond well to treatments such as excision, laser, cryotherapy, topical imiquimod, and topical timolol, but agminated PGs can be distressing to patients and challenging to treat. Topical sirolimus, an mTOR inhibitor, is used in the treatment of other vascular anomalies but has not been previously investigated for use in PGs. We report two patients with agminated PGs who demonstrated improvement in size, color, and bleeding following treatment with topical sirolimus."

Journal • Oncology • Pediatrics

Topical β-Blocker as a Novel Treatment Option for Periungual Pyogenic Granuloma: A Retrospective Study of Lesion Size Reduction and Pain Improvement. (PubMed, J Dermatol) - "No significant adverse events, including significant changes in blood pressure or heart rate, were observed. In conclusion, the study suggests that topical timolol is a safe and effective treatment for periungual PG, making it a valuable supportive care strategy for patients undergoing anticancer therapy."

Journal • Retrospective data • Dermatology • Mood Disorders • Oncology • Pain